Testing DNA repair marker for PARP inhibitor resistance
Part of Cancer, Skin clinical trials.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have confirmed breast cancer on lab pathology
- Your cancer is locally advanced or has spread (metastatic), and it’s HER2-negative
- Your tumor is either hormone receptor positive (ER/PR ≥ 1%) or triple-negative (ER and PR both < 1%, and HER2-negative)
- You have a harmful (deleterious) germline BRCA1 and/or BRCA2 mutation and are eligible for PARP inhibitor treatment (olaparib or talazoparib)
- You must be able to have a biopsy of a site other than bone (or have a usable biopsy already stored from the last 3 months with both frozen and FFPE samples)
- You can take part and follow the study plan (good enough general health, ECOG score 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that looks for cancer cells in your blood and checks if your tumor has a specific feature linked to DNA repair. The goal is to see if this blood test can help guide whether PARP inhibitor medicines—which target cancers with this feature—might work for you.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.